News

BioSpace1d

Sarepta Fallout Continues With EU’s Negative Opinion of Elevidys in Ambulatory Patients

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...
Dealbreaker on MSN5d

Sarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’

Financial analysts lambasted Sarepta executives for failing to disclose a drug-test fatality when the company announced a ...
Investor's Business Daily on MSN1d

Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe

Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy ...

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and ...
BioSpace9d

Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Zimmer Biomet Holdings (ZBH) and Eli Lilly & Co (LLY)

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
STAT5dOpinion

The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...